Day One Biopharmaceuticals (NasdaqGS:DAWN) FY Conference Transcript

Summary of Day One Biopharmaceuticals FY Conference Call Company Overview - Company: Day One Biopharmaceuticals (NasdaqGS:DAWN) - Core Product: OJEMDA, approved for pediatric low-grade glioma [3][4] Financial Performance - 2025 Revenue: Over $155 million, marking the first full year of OJEMDA's launch - Year-over-Year Growth: 170% increase in revenue [4] - Q4 2025 Revenue: Over $52 million, with a 37% growth quarter-over-quarter [4] - 2026 Revenue Guidance: Projected between $225 million and $250 million, indicating approximately 50% growth year-over-year [30] Key Metrics for Growth - New Patient Starts (NPS): Increased by 25% in the second half of 2025 compared to the first half [12] - Duration of Therapy: Mean duration approximately 17 months, median duration 19 months, indicating strong patient retention [13] Pipeline Developments - Emi-Le Program: A B7-H4-targeted ADC for adenoid cystic carcinoma, with data expected mid-2026 [6] - DAY301 Program: A PTK7-targeted ADC, initial clinical data anticipated in the second half of 2026 [6][41] OJEMDA Launch Insights - Frontline Enrollment: Expected completion in the first half of 2026 [5] - Second Line Use: Increasing familiarity among physicians is driving more second-line usage of OJEMDA [15][21] - Education and Data: Ongoing education for KOLs and physicians is crucial for increasing patient starts and therapy persistence [22][27] Clinical Data and Impact - Treatment-Free Interval: Median time to next therapy after OJEMDA is approximately 43 months, with nearly 80% of children remaining off therapy after one year [25][27] - Physician Engagement: Positive data from ASCO and other conferences are expected to enhance physician confidence and patient management [23][28] Strategic Focus - Durable Growth Story: The company aims to establish OJEMDA as a standard of care in second-line treatment for pediatric low-grade glioma [60] - Employee Commitment: Acknowledgment of the team's efforts in executing the company's strategy and managing acquisitions effectively [60] Conclusion - Day One Biopharmaceuticals is positioned for significant growth driven by the successful launch of OJEMDA and a robust pipeline. The focus on education, data dissemination, and patient management strategies will be critical in achieving the projected revenue targets and expanding market presence.